Applied Therapeutics Stock Price, News & Analysis

Applied Therapeutics (Nasdaq: APLT), a clinical-stage biopharmaceutical company, will present at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 10:00 a.m. ET. Investors can access the webcast on their website, with a replay available afterward.

The company is focused on developing drug candidates for high unmet medical needs, including AT-007 for Galactosemia and AT-001 for Diabetic Cardiomyopathy. Their clinical trials seek to address critical health issues in rare diseases.

Applied Therapeutics (APLT) reported its Q1 2021 financial results, ending the quarter with $148.1 million in cash and cash equivalents. The company continues to develop therapies for high unmet medical needs, including AT-007 for Galactosemia and SORD Deficiency. A Phase 2 pilot study of AT-007 has commenced, and a New Drug Application (NDA) submission for Galactosemia is anticipated by Q3 2021. However, the company reported a net loss of $24.2 million, or $1.00 per share, increasing from a loss of $12.4 million in Q1 2020.

Applied Therapeutics (Nasdaq: APLT) announced a poster presentation at the 2021 Annual Clinical Genetics Meeting of ACMG, held from April 13-16. The presentation focuses on the progressive worsening of the central nervous system phenotype in children with Classic Galactosemia. Riccardo Perfetti, Chief Medical Officer, stated the urgency for disease-modifying therapies based on the findings. The poster, titled 'Progressive Worsening of CNS Phenotype in Children with Classic Galactosemia', will be accessible on the ACMG website.

Applied Therapeutics (APLT) recently announced important developments including the resumption of the AT-007 ACTION-Galactosemia Kids pediatric clinical study, with a New Drug Application (NDA) submission targeted for Q3 2021.

The company also successfully closed a public offering, raising approximately $74.3 million, enhancing its cash position to $96.8 million. Additionally, research and development expenses surged to $61.8 million, reflecting increased clinical activities. However, the net loss for 2020 widened to $94.0 million, indicating growing financial challenges.

Applied Therapeutics (Nasdaq: APLT) announces a Virtual Rare Disease Forum on March 23, 2021, from 1:00pm to 3:00pm ET to showcase its drug development programs for Galactosemia, SORD Deficiency, and PMM2-CDG. Key updates will include insights on the ACTION-Galactosemia program and updates on SORD and PMM2-CDG clinical development plans. The event aims to highlight the potential of its lead candidate AT-007 in addressing rare diseases. An audio webcast will be available live, with details found on their official website.

Applied Therapeutics, Inc. (Nasdaq: APLT) announced its participation in two investor conferences in March 2021. The first is the Cowen 41st Annual Health Care Conference on March 2, 2021, from 9:10 to 9:40 a.m. ET. The second is the Barclays Global Healthcare Conference scheduled for March 9, 2021, from 4:45 to 5:10 p.m. ET. The webcasts will be available on their website's Investor Relations section, with a replay option post-event. Applied Therapeutics develops novel drug candidates targeting high unmet medical needs, including treatments for rare diseases.

Applied Therapeutics (NASDAQ: APLT) has completed a public offering of 3,000,000 shares at $23.00 each, raising approximately $64.6 million net of expenses. The offering closed on February 17, 2021, with underwriters exercising an option for an additional 450,000 shares. The funds will be utilized to advance clinical and preclinical development of its drug candidates and general corporate purposes. The offering was managed by Goldman Sachs & Co. LLC, Cowen, and UBS Investment Bank.

Applied Therapeutics, Inc. (NASDAQ: APLT) has priced its underwritten public offering of 3,000,000 shares at $23.00 per share, expected to generate gross proceeds of $69 million. The offering, which could increase by an additional 450,000 shares if underwriters exercise their options, will close on February 17, 2021. The funds will be utilized for advancing clinical and preclinical developments as well as general corporate purposes. Goldman Sachs, Cowen, and UBS are the joint book-running managers for this offering.

Applied Therapeutics (NASDAQ: APLT) announced a public offering of 3,000,000 shares of its common stock, with an additional 450,000 shares available for underwriters. The company plans to use the proceeds for clinical and preclinical development, commercialization efforts, and general corporate purposes. Goldman Sachs, Cowen, and UBS are the joint book-running managers for this offering. The offering's completion is subject to market conditions, and the company emphasizes that this press release does not constitute an offer to sell these securities.